# Pizarra — PT-pseudo_cac2563c222a (task 1)

## [1] CASE FILE

**INTAKE** — *the patient record, verbatim; adds no interpretation*

The structured clinical record below is the read-only panel the urologist sees up front, exactly as it arrives in this patient's record. The documents it refers to are masked and must be retrieved.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_cac2563c222a
Task: 1

Encounter: Urology - outpatient on 28 Feb 2025.
Referrer: Dr. F. de Boer (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 50-year-old male
  - PSA: 4.53 ng/mL
  - mpMRI — PI-RADS score: 5 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.12 ng/mL²
  - PSA velocity: 0.54 ng/mL/yr
  - Prior PSA: 4.1 ng/mL
  - Prostate volume: 41.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.84312165 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NSAIDs
  - Additional notes: PSA 4.53 ng/mL. PI-RADS 5. PSAD 0.12. Prostate volume 41 mL. csPCa 0.84.

Vitals: weight 86 kg, height 182 cm, BMI 26.0, BP 143/64 mmHg, HR 64 bpm. Smoking: Non-smoker.

Chief complaint: Assessment requested to review a previous prostate biopsy alongside a steadily climbing PSA curve.

History: A 50-year-old freelance translator residing with his wife came under scrutiny after a PSA elevation emerged in mid-2023. He denies any lower urinary tract complaints, recording an IPSS of 1 out of 35, and reports no pelvic discomfort or blood in the urine. A non-smoker, he drinks roughly 26 alcoholic units each week and stays physically active through weekend hiking excursions. Unrelated recent visits included a dermatology check for actinic keratosis monitoring and a routine flu shot given by the practice nurse. He has never undergone major operations, uses no daily prescriptions, and handles remote work using enlarged print because of mild vision loss. Despite some mild worry about the PSA curve, he feels otherwise healthy. The prior biopsy bucket is Positive.

Physical examination: DRE — texture: smooth and symmetrically normal; mobility: unrestricted; asymmetry: absent. General inspection shows stable vital signs, clear peripheral lymph nodes, and no skeletal tenderness. Abdominal palpation confirms a soft, non-tender cavity devoid of masses.

Patient info: freelance translator; Married; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 26 units / week; exercise Hiking on weekends; IPSS score: 1/35 (mild LUTS).

Recent other appointments: Dermatology — actinic keratosis check; GP practice nurse — flu vaccination.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


[Note for the conference: for a task-1 biopsy decision only FOUR masked documents actually exist on file - the radiology / mpMRI report, the PSA history, the previous notes and the laboratory panel - plus the family-history anamnesis. There is no pathology report to retrieve for this task; the prior-biopsy status shown in the panel above is all the pathology information on record.]

## [2] INITIAL RECOMMENDATION (statistical prior)

**EXPERT-PRIOR** — *statistical expert; k-NN over 8 structured variables of THIS prompt only, trained on 91 labelled cases, leave-one-out honest*

A basic classifier, whose sole purpose is to provide a suggestion, produces this result along with its associated uncertainty. The purpose of this decision is to use it as an initial reference point for discussing the results.

SUGGESTION: BIOPSY
  p(biopsy = yes) = 0.63 +/- 0.20   (95% CI 0.22-0.95)

Where the uncertainty comes from:
  - aleatoric  dA = 0.17  (the nearest labelled cases disagree with each other)
  - epistemic  dA = 0.11  (few labelled cases resemble this one)
  - 5.2 effective neighbours out of 10; 5 of the 5 closest labelled cases were biopsied
  - 80%-coverage conformal set: {yes}

TIER 'discuss': A +/- dA straddles 0.5. The classifier genuinely CANNOT tell these two answers apart; measured accuracy in this tier is 0.61, barely above the 0.62 majority-class rate. Its number is a starting point only, and the case must be decided on the clinical evidence retrieved by the other participants.

Variables it actually read (from the visible panel only, no documents retrieved):
  pirads=5.0, bx_ord=3.0, psa=4.53, age=50.0, psad=0.12, dre_ord=0.0, vol=41.0, n_pmhx=0.0
  missing / not evaluable: none

Out-of-fold performance of this recommender on the 91 labelled cases (5x5 CV):
  accuracy 0.703, balanced accuracy 0.662, AUC 0.75, ECE 0.095.
It is right about 7 times out of 10 overall. It is NOT an oracle and it has never seen the
radiology report, the PSA trajectory, the laboratory panel or the previous notes.

## [3] GAPS AND DOUBTS

**LLM-1-GAP-ANALYST** — *raises doubt only; has no access to clinical documents and issues no recommendation*

WHAT THE PRIOR CANNOT SEE
  The statistical recommender relied only on the structured panel. It could not weigh the specific PSA velocity (0.54 ng/mL/yr) or the trend of the prior PSA (4.1 ng/mL to 4.53 ng/mL over 3 months), which are crucial for assessing the rate of change. It also missed the content of the mpMRI report (PI-RADS 5) and the full laboratory panel, which might provide context for the PSA density or other markers.

WHY THE SUGGESTION COULD BE WRONG
  The prior suggests BIOPSY with a wide uncertainty interval (0.63 +/- 0.20). This wide interval suggests the input features are highly ambiguous. A failure mode is the contradiction between the high csPCa predicted probability (0.843) and the normal DRE findings, which might suggest a benign finding despite the high imaging score. Another failure mode is the prior positive biopsy status; if the prior biopsy was positive, the question "does he have cancer" is fundamentally different from a screening question, potentially making the initial suggestion inappropriate.

WHAT TO RETRIEVE, AND WHAT WOULD CHANGE THE ANSWER
  <document> radiology / mpMRI report -> If the report details specific suspicious lesions or features, it would refine the PI-RADS 5 assessment.
  <document> PSA history (trend / velocity beyond the headline value) -> If the trend is highly aggressive, it would increase the urgency for intervention.
  <document> previous GP / urology consultation notes -> These notes might contain context regarding the clinical suspicion or previous management plans.
  <document> laboratory results (full panel) -> This could provide context for the PSA density or other relevant biomarkers.

## [4] EVIDENCE REPORT

**LLM-2-EVIDENCE** — *the only participant who retrieved documents; reports findings, not verdicts*

RETRIEVED
  One block per document you opened. Quote the values and phrases that matter, verbatim and with units. Numbers, lesion descriptions, dates, explicit radiologist or clinician recommendations. Do not paraphrase a number.
  
  **radiology / mpMRI report**
  {"case_id": "PT-pseudo_cac2563c222a", "radiology_report": "Subject: Multiparametric MRI of the Prostate | Date: 15 Feb 2025 | Institution: Ziekenhuis Gelderse Vallei (Ede)\nClinical Indication:\nFollow-up assessment after an earlier prostate biopsy. The latest PSA reading is 4.53 ng/mL, and the prior scan carried a PI-RADS 5 rating.\nFINDINGS:\nTotal gland volume registers at 41.0 mL. T2-weighted sequences highlight a sharply demarcated hypointense area within the right peripheral zone at the mid-gland level, spanning roughly 12 mm. Diffusion-weighted imaging shows pronounced restricted diffusion, mirrored by diminished signal on the ADC map. Dynamic contrast-enhancement captures early focal uptake inside the abnormality. Seminal vesicles maintain normal calibre and signal characteristics. Pelvic lymph nodes appear benign. No extracapsular extension or seminal vesicle invasion is evident.\nIMPRESSION:\nPI-RADS 5 lesion in the right mid-peripheral zone. Prostate volume 41.0 mL yielding a PSA density of 0.12 ng/mL/mL. csPCa predicted probability 0.84312165."}
  
  **PSA history**
  {"case_id": "PT-pseudo_cac2563c222a", "psa_trend": [{"date": "Jun 2023", "val": 3.3}, {"date": "Jan 2024", "val": 3.7}, {"date": "Aug 2024", "val": 4.1}, {"date": "Feb 2025", "val": 4.53}]}
  
  **laboratory results**
  {"case_id": "PT-pseudo_cac222a", "laboratory_results": [{"name": "PSA", "val": "4.5 ng/mL", "date": "13 Feb 2025", "flag": "H"}, {"name": "Free PSA", "val": "1.10 ng/mL", "date": "13 Feb 2025", "flag": ""}, {"name": "%Free PSA", "val": "24%", "date": "13 Feb 2025", "flag": ""}, {"name": "Haemoglobin", "val": "14.0 g/dL", "date": "13 Feb 2025", "flag": ""}, {"name": "WBC", "val": "6.8 x10^9/L", "date": "13 Feb 2025", "flag": ""}, {"name": "Platelets", "val": "187 x10^9/L", "date": "13 Feb 2025", "flag": ""}, {"name": "Creatinine", "val": "98 umol/L", "date": "13 Feb 2025", "flag": ""}, {"name": "eGFR", "val": ">60 mL/min/1.73m2", "date": "13 Feb 2025", "flag": ""}, {"name": "Testosterone", "val": "14.4 nmol/L", "date": "13 Feb 2025", "flag": ""}, {"name": "Alkaline phosphatase", "val": "63 U/L", "date": "13 Feb 2025", "flag": ""}, {"name": "LDH", "val": "175 U/L", "date": "13 Feb 2025", "flag": ""}]}
  
  **previous GP / urology consultation notes**
  {"case_id": "PT-pseudo_cac222a", "previous_notes": [{"date": "11 Mar 2023", "author": "Dr. F. de Boer (GP)", "text": "Initial laboratory screening in late 2022 recorded a PSA level of 3.2 ng/mL, which climbed to 3.4 ng/mL by June 2023. Because of this upward trend, a urology referral was initiated to arrange further assessment and book the initial biopsy."}, {"date": "07 Sep 2023", "author": "Dr. F. de Boer (GP)", "text": "Post-consultation update indicates the earlier biopsy established Gleason 3+3 disease. The current PSA measures 3.5 ng/mL. Clinical notes document the ongoing surveillance plan."}]}

NOT RETRIEVED
  get_family_history - Not called because the retrieval economy suggests it is not necessary for the immediate decision based on the other retrieved data.

WHAT THE EVIDENCE SUPPORTS
  FOR sampling this patient now:
  - mpMRI PI-RADS 5 lesion in the right mid-peripheral zone.
  - PSA velocity of 0.54 ng/mL/yr (from trend data).
  - csPCa predicted probability of 0.84312165.
  
  AGAINST sampling this patient now:
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done).
  - Prior biopsy status: Positive.
  
WHERE THIS LEANS
  The evidence strongly points towards sampling due to the high-risk imaging (PI-RADS 5), rising PSA velocity, and high predicted cancer probability, which contradicts the benign DRE and prior positive biopsy. This leans toward the statistical prior's suggestion of BIOPSY.

[Sections actually revealed in this consultation: radiology_report, psa_trend, laboratory_results, previous_notes. Tools executed: get_lab_results, get_mri_report, get_previous_notes, get_psa_trend.]

## [5] IMAGE-EMBEDDING PREDICTOR

**EXPERT-IMAGE** — *image-embedding expert; frozen foundation-model MRI vectors behind a trained head*

Frozen foundation-model embeddings on file for this patient: MRI image (1 vector).
The raw vectors are never shown; only a compact score would be.

No calibrated head is deployed for the biopsy decision, so no score was produced. The probe that measured this modality for task 1 reported AUC 0.43 (at or below chance), which is why nothing is being asserted here.

Bottom line for the chair: the image-embedding route contributes NO usable evidence for this
biopsy decision. Decide on the structured panel, the retrieved documents and the guidelines.
Do not cite imaging-embedding support in the reasoning, and do not let the absence of a score
count as a negative finding.

## [6] FINAL DECISION AND FORM

**LLM-3-CHAIR** — *chairs the conference; the only participant who decides*

FINAL DECISION: BIOPSY   (confidence: clear)

Biopsy is recommended because the evidence strongly supports intervention due to a PI-RADS 5 lesion, a rising PSA velocity of 0.54 ng/mL/yr, and a high csPCa predicted probability of 0.843. This high-risk imaging and biochemical trend override the benign DRE findings and the prior positive biopsy status, which mandates re-evaluation.

Variables that carried weight: bx=decisive, dre=noted, psa=decisive, vol=noted, psad=important, pirads=decisive
Sections revealed: radiology_report, psa_trend, laboratory_results, previous_notes
